Agilent Technologies Launches New Products for Analyzing Biotherapeutics
News Jun 25, 2015
Agilent Technologies Inc. today announced two additions to its AdvanceBio product family, designed to provide rapid, reproducible results for scientists in the biopharmaceutical industry.
Agilent introduced the products — the AdvanceBio glycan-mapping workflow and the AdvanceBio oligonucleotide column — at HPLC 2015, an international symposium being held in Geneva, Switzerland, this week.
"Both of these new products will help researchers achieve faster, more reliable separations, lowering their cost per analysis," said Helen Stimson, Agilent vice president and general manager of the Chemistries and Supplies Division. "Like all AdvanceBio solutions, they are designed to deliver results that are easy to reproduce, increasing confidence in their accuracy and completeness — vital aspects of biopharmaceutical development."
The company's new AdvanceBio glycan-mapping workflow is a complete consumables workflow for deglycosylation, 2-AB labeling and HILIC glycan analysis using mass spectrometry and fluorescence detection. This unique workflow features AdvanceBio glycan-mapping columns, glycan standards and N-glycan sample-preparation kits, along with all the consumable components researchers require.
The product's comprehensive guides and standard methods provide researchers with everything they need to quickly identify and quantify glycans in a way that is easily reproducible.
The new AdvanceBio oligonucleotide column is the first high-pH, stable, superficially porous particle-based liquid chromatography column for oligonucleotide analysis. It builds on Agilent's innovations in superficially porous silica-based columns for biomolecule separations, which began with the Poroshell 300 in 2001 and includes AdvanceBio peptide-mapping, glycan-mapping and RP-mAb columns.
The right particle design gives researchers the flexibility to use high-performance or ultra-high-performance liquid chromatography systems. The increased flexibility also allows them to make more efficient use of existing laboratory resources, thus reducing costs.
AdvanceBio oligonucleotide columns and oligonucleotide standards improve the reliability of results and reduce costs for therapeutic oligonucleotide analysis.
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE